Patents by Inventor Rajinder Singh

Rajinder Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I
    Patent number: 9790173
    Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: October 17, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen
  • Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
    Publication number: 20170291909
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: November 23, 2016
    Publication date: October 12, 2017
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda, Thomas Sun, Valentino J. Stella
  • Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
    Patent number: 9763941
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methyl -sulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 19, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
    Patent number: 9751893
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: September 5, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
  • 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
    Publication number: 20170246167
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Application
    Filed: February 27, 2017
    Publication date: August 31, 2017
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossii
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent number: 9737554
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: August 22, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 9732073
    Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 15, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
  • Protein kinase C inhibitors and uses thereof
    Patent number: 9732070
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 15, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Kin Tso, Jing Zhang, Matthew Duncton, Salvador Alvarez, Rao Kolluri, John Ramphal, Sacha Holland
  • Cycloalkyl substituted pyrimidinediamine compounds and their uses
    Patent number: 9725419
    Abstract: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: August 8, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Ankush Argade, Rajinder Singh, Sambaiah Thota, David Carroll, Kin Tso, Vanessa Taylor, John McLaughlin, Vadim Markovtsov
  • Respiratory protection equipment
    Patent number: 9724546
    Abstract: A respirator has one or more electrodes of e.g. conductive elastomer disposed on the surface of a face sealing member opposite to the surface which seals against the user's face. In use the integrity of the seal formed between the sealing member and the user's face is monitored by monitoring the electrical capacitance across that member between the electrode(s) and the user's face.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: August 8, 2017
    Assignee: QINETIQ LIMITED
    Inventors: Adrian Huggins, Bernard Robert Money, Rajinder Singh, David Thomas Steele
  • Nrf2 Activating Compounds and Uses Thereof
    Publication number: 20170217922
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: February 2, 2017
    Publication date: August 3, 2017
    Inventors: Matthew Duncton, Rajinder Singh
  • Nrf2 Activating Compounds and Uses Thereof
    Publication number: 20170217932
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 3, 2017
    Inventors: Matthew Duncton, Rajinder Singh
  • 2-OXINDOLE COMPOUNDS
    Publication number: 20170204087
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Application
    Filed: January 18, 2017
    Publication date: July 20, 2017
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20170202837
    Abstract: This invention relates to solid oral pharmaceutical formulations or(S)-methyl ((4(4-(3-(5-chtoro-2-fluoro-3-(methyl-sutfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Application
    Filed: March 7, 2017
    Publication date: July 20, 2017
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • Asset monitoring and tracking with a distributed Bluetooth low energy (BTLE) sensor system of heterogeneous sensors over wireless networks
    Patent number: 9712953
    Abstract: One or more Bluetooth assets having a Bluetooth radio are associated with a specific set of business rules by enterprise users. Scan event data is received from at least one of a plurality of Bluetooth sensors having Bluetooth radios, wirelessly distributed around a communication network. The scan event data results from a scan event wherein the Bluetooth asset was within range of the at least one Bluetooth sensor. The scan event is analyzed against the business rules. Responsive to determining that at scan event meets at least one condition of at least one of the specific set of business rules, a notification can be sent. One specific implementation in a smart car seat safety system notifies a parent when a child is unintentionally left in a smart car seat.
    Type: Grant
    Filed: November 15, 2015
    Date of Patent: July 18, 2017
    Inventors: Rajinder Singh, Ihab Abu-Hakima, Gurpreet Singh Bal
  • Tetrazolones as a carboxylic acid bioisosteres
    Patent number: 9701647
    Abstract: The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 11, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Matthew Duncton, Rajinder Singh
  • Protein kinase C inhibitors and uses thereof
    Patent number: 9682976
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: June 20, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Matthew Duncton, Jing Zhang, Salvador Alvarez, Kin Tso, Sacha Holland, Rose Yen, Rao Kolluri, Thilo Heckrodt, Yan Chen, Esteban Masuda, Hui Li, Donald G. Payan, Ryan Kelley
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20170158683
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 8, 2017
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • 2,4-Pyrimidinediamine Compounds and Their Uses
    Publication number: 20170151239
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Application
    Filed: July 8, 2016
    Publication date: June 1, 2017
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander Rossi
  • Protein Kinase C Inhibitors and Uses Thereof
    Publication number: 20170152246
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: September 9, 2016
    Publication date: June 1, 2017
    Inventors: Rajinder Singh, Kin Tso, Jing Zhang, Matthew Duncton, Salvador Alvarez, Rao Kolluri, John Ramphal, Sacha Holland